Empagliflozin in Patients with Chronic Kidney Disease
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index; 19 of the 28 sources its claims cite were checked for support.
Abstract
Trial of empagliflozin in a broad chronic kidney disease population.
Overview
CoChat Summary
TL;DR
Empagliflozin 10 mg daily reduced the risk of the composite of kidney disease progression or cardiovascular death in the EMPA-KIDNEY randomized trial of 6609 people with chronic kidney disease. Benefits were consistent with and without diabetes and across the eGFR range studied, with no clear increase in serious adverse events overall.
Key findings
- The primary composite outcome occurred in 432 of 3304 patients (13.1%) on empagliflozin versus 558 of 3305 (16.9%) on placebo; hazard ratio 0.72 (95% CI 0.64 to 0.82; P<0.001).
- All-cause hospitalizations were fewer with empagliflozin: 24.8 versus 29.2 hospitalizations per 100 patient-years; hazard ratio 0.86 (95% CI 0.78 to 0.95; P=0.003).
- There was no statistically significant effect on hospitalization for heart failure or cardiovascular death (4.0% vs 4.6%; hazard ratio 0.84, 95% CI 0.67 to 1.07; P=0.15) or death from any cause (4.5% vs 5.1%; hazard ratio 0.87, 95% CI 0.70 to 1.08; P=0.21).
- Empagliflozin slowed eGFR decline: the between-group difference in chronic slope was 1.37 ml/min/1.73 m² per year (95% CI 1.16 to 1.59), and urinary ACR was reduced by 19% (95% CI 15% to 23%).
Methods
- Multicenter, international, randomized, double-blind, placebo-controlled trial conducted at 241 centers in 8 countries; 6609 participants were randomized to empagliflozin 10 mg once daily or matching placebo.
- Eligible adults had CKD with eGFR ≥20 to <45 ml/min/1.73 m², or eGFR ≥45 to <90 ml/min/1.73 m² with urinary ACR ≥200 mg/g; patients with or without diabetes were eligible, and those with polycystic kidney disease or a kidney transplant were excluded.
- Primary analysis used intention-to-treat Cox regression adjusted for age, sex, prior diabetes, eGFR, urinary ACR, and region; key secondary outcomes were multiplicity-adjusted, and eGFR slope was assessed with shared parameter models.
Limitations
- The paper states that the lower-than-expected cardiovascular event rate reduced statistical power for secondary or tertiary cardiovascular outcomes.
- Evident from the text: the trial was stopped early for efficacy at an interim analysis, so follow-up was relatively short (median 2.0 years).
- Evident from the text: some subgroup estimates, especially for lower albuminuria strata, were limited by fewer primary outcome events.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
10 Valid · 0 Not valid · 4 Not checked · 40 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A prespecified subgroup analysis from a trial of the SGLT2 inhibitor dapagliflozin in patients with CKD and a urinary ACR of at least 200 mg/g, found that kidney benefits extended to patients without diabetes”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Conclusions
What the sources say
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Abstract (p. 1437) specifies a urinary albumin-to-creatinine ratio of 200–5000 mg/g. Figure 2 identifies diabetes status as a prespecified subgroup, and the Discussion states that kidney-protective effects extended to participants with chronic kidney disease without type 2 diabetes. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [12] Wheeler DC Stefansson BV Jongs N Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial Lancet Diabetes Endocrinol 2021 9 1 22 31 10.1016/S2213-8587(20)30369-7 33338413 source
- Supportedcites [13] Staplin N Roddick AJ Emberson J Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials EClinicalMedicine 2021 41 101163 10.1016/j.eclinm.2021.101163 34765951 PMC8571171 source
The Results (Eligible trial characteristics) identify DAPA-CKD as a dapagliflozin trial in patients with CKD and urinary ACR of 200–5000 mg/g. The Results (Relative effects of SGLT-2 inhibitors) report that the effect on kidney disease progression in the CKD trial appeared similar with and without diabetes; the References identify the underlying DAPA-CKD work as a prespecified analysis. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The effect of SGLT2 inhibition on kidney disease progression or cardiovascular death seen in the present trial is quantitatively similar to that seen in two other large placebo-controlled trials in CKD populations.6,7”
§ Empagliflozin in Patients with Chronic Kidney Disease > Discussion
What the sources say
- Supportedcites [6] Perkovic V Jardine MJ Neal B Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy N Engl J Med 2019 380 24 2295 2306 10.1056/NEJMoa1811744 30990260 source
The Methods identify CREDENCE as a placebo-controlled trial in patients with type 2 diabetes and albuminuric CKD. Table 2 reports a hazard ratio of 0.70 for its primary composite of kidney disease progression or renal or cardiovascular death. This supports the citation’s role as one of the two earlier CKD trials; the paper does not itself compare its result with EMPA-KIDNEY. (LLM, conf=0.88)
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Efficacy Outcomes table reports that DAPA-CKD was a placebo-controlled trial in patients with chronic kidney disease and found a lower risk of the kidney-progression or cardiovascular-death composite with dapagliflozin (hazard ratio, 0.61). The cited paper supplies one of the two trial results; the statement that its effect is quantitatively similar to EMPA-KIDNEY is the citing authors’ comparison, not a finding attributed to this paper alone. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“or death from any cause (4.5% vs 5.1%)”
- Also stated in: § Primary and Secondary Outcomes · plain
“or on death from any cause (hazard ratio, 0.87; 95% CI 0.70 to 1.08; P=0.21)”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The rates of serious adverse events were broadly similar in the two groups.”
- Also stated in: § Safety Outcomes and Adverse Events · hedged
“There was no apparent evidence that empagliflozin increased the incidence of serious adverse events overall, or in any particular MedDRA system organ class (Table S8).”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Safety Outcomes and Adverse Events · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were fewer hospitalizations from any cause in the empagliflozin group (0.86; 0.78 to 0.95, P=0.003)”
- Also stated in: § Primary and Secondary Outcomes · plain
“there were significantly fewer first and subsequent hospitalizations from any cause in the empagliflozin group (24.8 versus 29.2 hospitalizations per 100 patient years: hazard ratio, 0.86; 95% CI 0.78 to 0.95, P=0.003)”
- Also stated in: § Discussion · plain
“Risk of hospitalization for any cause was also reduced by 14%.”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
17 more claims
Create a free account to see all 54 claims and every source verdict.
- It may state two separate claims as one. 24
- Probably not a substantial claim. 16
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozintreated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [115]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozin-treated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [128]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Dedicated kidney outcomes trials in people with CKD and type 2 diabetes have shown that the SGLT2 inhibitors empagliflozin, canagliflozin, and dapagliflozin have beneficial effects on slowing progression of CKD and CV outcomes in this population (139-141).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [141]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, SGLT2i have been studied specifically among patients with CKD with or without T2D in 3 completed primary kidney outcome trials (CREDENCE[15], DAPA-CKD[16], and EMPA-KIDNEY[17]), which showed benefit for both a significant reduction in the primary kidney outcomes and cardiovascular outcomes [18,19].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“The DAPA-CKD and FIDELIO trials enrolled patients with eGFR ≥25 mL/min/1.73 m2 and the EMPA-KIDNEY trial enrolled patients with eGFR ≥20 mL/min/1.73 m2; results demonstrated that dapagliflozin, finerenone and empagliflozin are effective and safe in these patients, although safety data are lacking for initiating therapy below these thresholds [16,17,22].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493 · cited 1×
“…kidney disease with increased levels of albuminuria, large placebo-controlled trials have shown that renin-angiotensin system (RAS) inhibitors, 3–5 sodium-glucose cotransporter 2 (SGLT2) inhibitors, 6,7 and the non-steroidal mineralocorticoid receptor antagonist finerenone 8,9 all reduced the…”
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 2×
“6,7 The CREDENCE trial of canagliflozin required all participants to have type 2 diabetes and a urinary ACR of at least 300 mg/g, and excluded patients with an eGFR of less than 30 ml per minute per 1.73 m 2 .”
InfluentialLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618 · cited 3×
“…with an estimated GFR (eGFR) below 30 ml per minute per 1.73 m 2 or on how these benefits might vary among the wider range of patients with CKD. 7,12,13 This multicenter international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess…”
InfluentialThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Cited by
Items 1,601–1,700 of 2,656
What to do with key cardiovascular drugs when kidney function worsens?
Bergen, K., & Spaak, J. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf354 · Cited by 1
“However, the long-term nephroprotective effects have been proved by several large RCTs [119 –121 ].”
RAY, A. S., Errabelli, P. K., Lathiya, M. K., & Mareedu, N. (2025) · Frontiers in Nephrology · doi:10.3389/fneph.2025.1673799 · Cited by 1
Proteinuria After Kidney Transplantation
Seeman, T., Myette, R. L., Feber, J., Bertacchi, M., Dandamudi, R., Erez, D. L., & Buescher, A. K. (2025) · Pediatric Transplantation · doi:10.1111/petr.70233 · Cited by 2
Hamed, S., Kalampokas, N., Beckendorf, J., et al. (2025) · ASAIO Journal · doi:10.1097/mat.0000000000002608 · Cited by 1
Navarrete, R. E. T., Freitas, J. C., Fonseca, I. M., Cunha, A., de Sá, J. R., & Martins, L. S. (2025) · Diabetology · doi:10.3390/diabetology6120158 · Cited by 1
Cortinovis, M., Perico, N., & Remuzzi, G. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000975 · Cited by 1
Li, C., Ng, J. K., Chan, G. C., Fung, W. W., Chow, K., & Szeto, C. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04677-0 · Cited by 2
“For patients with advanced CKD, SGLT2 inhibitors have minimal glucose-lowering effect, yet still provide comparable long-term benefits [31, 32].”
Chronic kidney disease progression after cardiac surgery: a retrospective multicentre study
Bille, S., Lindhardt, R. B., Riber, L. P., Juhl‐Olsen, P., Ravn, H. B., & Rasmussen, S. B. (2025) · BJA Open · doi:10.1016/j.bjao.2025.100506 · Cited by 2
Mahboub, B. M., Refaie, A. F., El-Haggar, S. M., Hafez, Y. M., & Mostafa, T. M. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-02040-9 · Cited by 2
Checa-Ros, A., Okojie, O. J., Steib, N., Bellasi, A., Salvador-Martínez, P., Isabel, F., & D’Marco, L. (2025) · International Urology and Nephrology · doi:10.1007/s11255-025-04965-6 · Cited by 2
Zlatkina, V. V., Nesen, А. О., & Demikhova, N. V. (2025) · Ukrainian Journal of Nephrology and Dialysis · doi:10.31450/ukrjnd.4(88).2025.10 · Cited by 1
López-Garrigós, M., Puig, E., Sánchez, S., Gutierrez, I., Salinas, M., Ortiz, A., & Flores, E. (2025) · Diagnostics · doi:10.3390/diagnostics16010008 · Cited by 1
Lee, S., Han, K. A., Hong, E., Kang, J. G., Chung, C. H., Won, J. C., Jeon, E. J., Cho, J. H., Cho, H., Kim, S. G., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70386 · Cited by 2
Effects of dapagliflozin in IgA-nephropathy in real clinical practice
Khrabrova, M. S., & Panaetova, S. K. (2025) · Новые Санкт-Петербургские врачебные ведомости. · doi:10.24884/1609-2201-2025-104-3-59-67 · Cited by 2
Harrington, J., Severino, A., Yanek, L. R., Fida, N., Ishaq, F., Al-Saffar, F., Song, E., Clark, K. A. A., Marco, T. D., Holzhauser, L., et al. (2025) · JHLT Open · doi:10.1016/j.jhlto.2025.100465 · Cited by 1
Merker, L., Ebert, T., Schleicher, E. D., Isermann, B. H., & Guthoff, M. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2592-8500 · Cited by 2
Cardiovascular Disease and Diabetes: A New Challenge in the Treatment and Management
Riccioni, G., Notarangelo, C., Riccioni, M., & D’Orazio, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010354 · Cited by 1
Non-diabetic Kidney Disease in Type 2 Diabetes: From Kidney Biopsy to Precision Medicine
Sreedharan, S., Mohandas, M. K., Vismaya, K. B., & Raju, N. (2026) · Cureus · doi:10.7759/cureus.100716 · Cited by 4
D’Elia, E., Limonta, R., Giaccherini, C., Basile, C., Sciatti, E., Zucchetti, O., Odoardo, L. A. F. D., D’Isa, S., Chiesa, E., Gori, M., et al. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvaf022 · Cited by 2
Zawadka, M., Taguiam, E., Lê, M., Sanjanwala, R., Liu, S., Shah, A. H., & Kunutsor, S. K. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70411 · Cited by 6
Pablo-Ortega, J., Aldana, D. R., Segura‐Fragoso, A., Mazon-Ramos, P., Portela‐Romero, M., Gonzalez-Juanatey, J. R., & Cinza‐Sanjurjo, S. (2026) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2025.102667 · Cited by 2
Asano, Y., Imaizumi, T., Katsurabayashi, Y., Sakurai, D., Takai, N., Toda, T., Miki, T., Maekawa, M., Kato, S., Hagiwara, Y., et al. (2026) · BMC Nephrology · doi:10.1186/s12882-025-04718-8 · Cited by 1
Rodríguez‐Espinosa, D., Parra, R., Mataj, B., et al. (2026) · Transplant International · doi:10.3389/ti.2025.15872 · Cited by 1
Lin, Y., Lin, T., Liao, P., et al. (2026) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70122 · Cited by 1
“The primary EMPA‐KIDNEY [29] and EMPA‐KIDNEY follow‐up trials [30] demonstrated that empagliflozin was beneficial in patients regardless of their diabetes status and across estimated glomerular filtration rate categories, with a carryover effect that lowers the risk of progression to end‐stage…”
Husain‐Syed, F., Yuecel, G., Daschner, C., Jochims, J., & Yazdani, B. (2026) · Cardiorenal Medicine · doi:10.1159/000550423 · Cited by 4
Cheng, Y., Kao, Y.-W., Chen, S., Chan, Y., & Chao, T. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1647342 · Cited by 3
Lamb, E. J., Barratt, J., Brettell, E. A., Cockwell, P., Dalton, R. N., Deeks, J. J., Eaglestone, G., Kalra, P. A., Khunti, K., Loud, F. C., et al. (2026) · BMJ Medicine · doi:10.1136/bmjmed-2025-001827 · Cited by 3
Bashier, A. M., Rukhaimi, M. A., Alhadari, A. K., Hussein, D., Hassanein, M. M., Abdelgadir, E., Rashid, F., Alhelfi, M., Kumar, D. N., Alalawi, F. J. A., et al. (2026) · Journal of Diabetes and Endocrine Practice · doi:10.1055/s-0045-1814429 · Cited by 1
A Hierarchical Composite Endpoint for CKD Progression in Patients with FSGS
Heerspink, H. J. L., Little, D. J., Gasparyan, S. B., Chertow, G. M., Toto, R. D., Rossing, P. R., Correa‐Rotter, R., Sjöström, C. D., Wheeler, D. C., & Jongs, N. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000994 · Cited by 1
Kidoguchi, S., Sugano, N., Suehiro, Y., & Yokoo, T. (2026) · BMC Nephrology · doi:10.1186/s12882-026-04765-9 · Cited by 1
Javier, R. M., Faizin, I., Andiani, Samudra, D., Puspitasari, R. A., Dharma, A. S., Nurpradika, B. Y., Amalia, F., Danny, S. S., Kuncoro, B. A. S., et al. (2026) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2026.200585 · Cited by 1
“Importantly, concerns regarding acute kidney injury were not substantiated; on the contrary, several trials reported lower rates of acute kidney injury with SGLT2 inhibition [9 – 11].”
InfluentialTakei, T., Tokuda, T., Yoshioka, N., Ogata, K., Tanaka, A., Kojima, S., Yamaguchi, K., Yanagiuchi, T., & Nakama, T. (2026) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2026.01.043 · Cited by 1
Santamaría, R., Escobar, C., Aranda, U., et al. (2026) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2026.501414 · Cited by 1
Heterogeneous Kidney Patterns in Diabetic Patients Following SGLT2 Inhibitor Use
Bae, S., Yun, D., Kim, J., Park, S., Kim, Y. C., Kim, D. K., Oh, K., Joo, K. W., Kim, Y. S., & Han, S. S. (2026) · Journal of Korean Medical Science · doi:10.3346/jkms.2026.41.e70 · Cited by 1
Zafar, A., Scarlata, C., & Jaleel, N. (2026) · Diabetic Medicine · doi:10.1111/dme.70254 · Cited by 2
Wong, C., Wu, M., Wu, M., et al. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-107969 · Cited by 1
Workforce Detachment in Persons with CKD
Rørth, R., Koch, M. M., Gerds, T. A., Carlson, N., Rossing, P. R., Kümler, T., Torp-Pedersen, C. T., Køber, L., & Chertow, G. M. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000001003 · Cited by 2
Nagasu, H., Nakashima, T., Ihara, K., Fujimori, R., Goto, T., Nitta, D., Kishi, S., Sasaki, T., & Kashihara, N. (2026) · Scientific Reports · doi:10.1038/s41598-026-38246-8 · Cited by 2
“Major trials such as CREDENCE and EMPA-KIDNEY have incorporated eGFR slope as an exploratory and tertiary outcome, respectively, while maintaining kidney composite outcomes as their primary endpoint 14,15 .”
Mitigating Risk of Kidney Dysfunction After Heart Transplantation and Therapeutic Approaches
DeFilippis, E. M., Cheng, R. K.-H., DONALD, E. M., Dunlay, S. M., Evangelista, L. S., Kamdar, F. D., Khazanie, P., Mohammed, S. F., Rossi, A., Spall, H. G. C. V., et al. (2026) · Circulation Heart Failure · doi:10.1161/circheartfailure.125.013747 · Cited by 1
Haidar, L., Crane, H. M., Nance, R. M., Doupe, M. B., Leong, C., Bamford, L. P., Burkholder, G., Cachay, E. R., Christopoulos, K., Commanday, A., et al. (2026) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000003854 · Cited by 2
RAS blockade in chronic kidney disease: Current evidence and future directions
Vitiello, A., Ponzo, A., Boccellino, M., & Zovi, A. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05140-z · Cited by 2
Taal, M. W. (2026) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2026.151692 · Cited by 1
Chatur, S., FLETCHER, R. A., Yeung, E. K., Siriwardana, A. N., Heath, L., Vaduganathan, M., Arnott, C. G., Badve, S. V., Kotwal, S. S., Jun, M., et al. (2026) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2026.01.020 · Cited by 1
Bellicini, M. G. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm45741 · Cited by 2
Elgazzar, R. A., & Ramadan, M. M. (2026) · Cureus · doi:10.7759/cureus.105114 · Cited by 4
Yanai, H., Adachi, H., Hakoshima, M., & Katsuyama, H. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062757 · Cited by 3
The ABCs of cardiovascular disease prevention: communicating what we know in 2026
Goren, L. R., Peng, A. W., Razavi, A. C., Blaha, M. J., Blumenthal, R. S., & Troy, A. L. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101570 · Cited by 2
“SGLT2i should be considered for patients with eGFR ≥ 20 mL/min/1.73 m 2 with or without the presence of type 2 diabetes to reduce progression of CKD and improve cardiovascular outcomes [71].”
InfluentialIs There a Role for Pentoxifylline in Diabetic Kidney Disease? A Mini Review
Leehey, D. J., & Agarwal, R. (2026) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2025.09.030 · Cited by 1
Dynamics and Predictive Values of Urinary Podocyte Biomarkers Following SGLT2 Inhibition in CKD
Urs, A., Moldovan, D. T., Rusu, C. C., Bondor, C. I., Potra, A. R., Tirinescu, D. C., Ţicală, M., Maslyennikov, Y., Bărar, A. A., Dînșoreanu, I., et al. (2026) · Life · doi:10.3390/life16030529 · Cited by 1
Handelsman, Y., Cheng, A. Y. Y., Fadini, G. P., Kushner, P. R., Bonnet, F., Fioretto, P., Kadowaki, T., Kanumilli, N., Cos, X., Frese, T., et al. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03559-7 · Cited by 1
Fejes, R., Jámbor, T., Szabó, A., & Tallósy, S. P. (2026) · Medical Sciences · doi:10.3390/medsci14020162 · Cited by 1
“…reinforce the robust renoprotective role of SGLT2 inhibitors in hyperuricemic T2DM—an effect magnitude aligned with large randomized controlled trials (e.g., DAPA-CKD, EMPA-KIDNEY)—while allopurinol appears effective primarily as urate-lowering therapy without comparable renal protection [32–34].”
Wong, K., Pitcher, D., Barratt, J., Gale, D. P., & RaDaR Consortium (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag066 · Cited by 2
Tian, Z., & Li, Y. (2026) · BMC Nephrology · doi:10.1186/s12882-026-04927-9 · Cited by 1
The effects of elevated phosphate on the kidney - damaging the gatekeeper
Mitchell, T., Verma, V., Fajol, A., & Faul, C. (2026) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-026-03160-5 · Cited by 4
Predicting Lifetime Risk of Kidney Failure Using Age and a Single eGFR Measurement
Enoki, R., Miyazaki, M., Imai, E., Tanaka, T., & Okamoto, K. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15072653 · Cited by 1
Natural History of Chronic Kidney Disease in Sickle Cell Disease
Ataga, K. I. (2026) · American Journal of Hematology · doi:10.1002/ajh.70300 · Cited by 1
Es, M. V., Erzeel, J., Wever, M. D., Dupont, M., Nijst, P., Penders, J., Tang, W. H. W., Savarese, G., Sprangers, B., Martens, P., et al. (2026) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcag054 · Cited by 1
Motofelea, A. C., Olariu, N., Pecingina, R., Marc, L., Chisavu, L. A., Bob, F. R., Mihăescu, A., Apostol, A., Schiller, O., Motofelea, N., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15082856 · Cited by 2
Novel Therapeutic Strategies for Patients With CKD and Diabetes Mellitus
Kugathasan, L., Katz, A., Muskiet, M. H. A., Sridhar, V. S., Scott, J., Yi, T. W., & Cherney, D. Z. I. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.106547 · Cited by 2
“…shift began with the emergence of sodium-glucose cotransporter (SGLT) inhibitors, 18 which demonstrated efficacy in reducing albuminuria, slowing the decline in estimated glomerular filtration rate (eGFR), and lowering ESKD risk 19-24 and cardiovascular events 19,25,26 in patients with CKD and T2D.”
Bahardoust, M., Rad, F. N., Mousavi, S., Shamohammadi, M., Haghmoradi, M., & Ghaffari, A. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70203 · Cited by 2
New Horizons in IgA Nephropathy: Approach to Current and Emerging Therapies
Madhavaram, S. K., Srinivas, S., Bhanushali, S. A., & Kalra, K. (2026) · Cureus · doi:10.7759/cureus.107347 · Cited by 2
“The Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY) trial demonstrated that the addition of empagliflozin slows CKD progression and reduces cardiovascular mortality in both diabetic and nondiabetic kidney disease [20].”
Suzuki, M., Fukuda, A., Kurimoto, R., Kudo, A., & Shibata, H. (2026) · Scientific Reports · doi:10.1038/s41598-026-49025-w · Cited by 1
Tedasen, A., Chatatikun, M., Netphakdee, R., Huang, J. C., & Phongphithakchai, A. (2026) · Life · doi:10.3390/life16050719 · Cited by 2
Remission in diabetic kidney disease: current evidence and future directions
Reaume, M., & Tangri, N. (2026) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001197 · Cited by 2
Nitric oxide redox signaling as a convergent mechanism in aging and fibrosis
Guo, X., Cao, Y., Liu, L., Peng, Y., Du, Y., Yang, F., & Huang, D. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103156 · Cited by 1
Kuo, Y.-J., Chen, L.-F., Chen, Y., Chen, P., & Lin, H. Y. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27094120 · Cited by 3
Nguyen, T., Hong, L., & Iso, T. (2026) · Cardiorenal Medicine · doi:10.1159/000552517 · Cited by 1
Montasser, M. E., Bargal, S. A., Streeten, E. A., Whitlatch, H. B., Yazdi, Z. S., Sirody, J., Kiplagat, R., Beshara, M., O’Connell, J. R., Taylor, S. I., et al. (2026) · Clinical and Translational Science · doi:10.1111/cts.70594 · Cited by 1
Utilización de ISGLT2 en receptores de trasplante renal sin diabetes mellitus
Gómez, P. F., Cano, M. L., Sánchez, E. V., Lizarazo, A., Sanchez-Montero, S., & Gómez, F. L. (2026) · Medicina Clínica · doi:10.1016/j.medcli.2026.107449 · Cited by 1
Mata, E., Resende, B. L., Castro, M., Português, J., Ribeiro, S., Gameiro, J., Lourenço, A., & Goncalves, L. (2026) · Korean Circulation Journal · doi:10.4070/kcj.2025.0466 · Cited by 1
Heinzl, M. W., Resl, M., Maier, J., Steinwender, C., Falkensammer, J., Fellinger, P., Steinmaurer, T., Saely, C. H., Hoppichler, F., Stingl, H., et al. (2026) · Wiener klinische Wochenschrift · doi:10.1007/s00508-025-02667-8 · Cited by 1
Tubulointerstitial inflammation and fibrosis induced by proteinuria: fresh insights
Cortinovis, M., Remuzzi, G., & Perico, N. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1837046 · Cited by 2
Carlino, I., Franco, S. D., Colalillo, N., Bisogno, S., Gennari, L., & Palazzuoli, A. (2026) · Biomedicines · doi:10.3390/biomedicines14061289 · Cited by 1
Stamouli, E., Trakatelli, C., Sarigianni, M., Kitsios, K., & Kotsis, V. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03239-4 · Cited by 3
Molecular Mechanisms and Clinical Applications of SGLT2 Inhibitors in Cardiovascular Diseases
Ma, C., Yang, P., Du, R., Yang, S., & Xu, Z. (2026) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-026-10794-4 · Cited by 1
“In nephrology, pivotal trials, including CREDENCE [49], DAPA-CKD [32], and EMPA-KIDNEY [50 ], established significant kidney-protective effects, as reflected by the slowed pro - gression of renal impairment and reduced incidence of end-stage renal disease among patients both with and without…”
Tomar, V., Çetin, T. E., Demirezen, A., Akçay, Ö. F., Derici, Ü., Güz, G., & Helvacı, Ö. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02200-5 · Cited by 1
Neumiller, J. J., Deng, Y., SWARNA, K. S., Polley, E. C., Herrin, J. S., Galindo, R. J., Umpierrez, G. E., Ross, J. S., Mickelson, M. M., Dryden, K., et al. (2026) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2026.04.007 · Cited by 1
Lim, R. S., Mingyao, B., Stanley, I. K., Biroš, E., & Mallett, A. J. (2026) · Advances in Kidney Disease and Health · doi:10.1053/j.akdh.2025.12.003 · Cited by 1
Mitochondrial Alterations and CKD: A Review
Pinzón-Cortés, J. A., Narongkiatikhun, P., Yuan, L., Meister, J., Hampson, H., van Raalte, D. H., Blondin, D. P., Capozzi, M. E., Sweet, I. R., Nelson, R. G., et al. (2026) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2026.01.021 · Cited by 2
Kaur, R., & Singh, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71031 · Cited by 1
“SGLT2 inhibitors subsequently demonstrated kidney and cardiovascular protection across the CREDENCE, DAPA-CKD, and EMPA-KIDNEY trials, earning a Grade 1A KDIGO recommendation irrespective of diabetes status [1, 2].”
Impact of impaired branched-chain amino acid metabolism on kidney disease
Kitada, M., Sugahara, S., Yasuda‒Yamahara, M., Kume, S., & Araki, S. (2026) · Clinical Science · doi:10.1042/cs20260961 · Cited by 1
Kim, Y., Jorge, A., Weber, B. N., & Costenbader, K. H. (2026) · Rheumatology · doi:10.1093/rheumatology/keag290 · Cited by 2
Lost in Stratification: Age Subgroup Analyses in CKD Progression Trials
Vart, P. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.106684 · Cited by 1
Dapagliflozin in Patients with Homozygous β-Thalassemia and Albuminuria
Tsiotsios, K., Vamvakas, S. M., Labropoulou, V., Lazaris, V., Davoulou, P., Kalavrizioti, D., Bratsiakou, A., Paraskevas, T., Kourakli, A., Goumenos, D. S., et al. (2026) · Acta Haematologica · doi:10.1159/000552285 · Cited by 1
Molecular, genetic, and pharmacological advances in type 2 diabetes (2015–2025)
Romero, R. C. (2026) · BioMolecular Concepts · doi:10.1515/bmc-2025-0059 · Cited by 1
Kahvecioğlu, S., Celik, H., Yalcinkaya, A. S., Boz, S. E. G., Ozdemir, P., Akarsu, Ö., Şensoy, N. Ö., & Aktaş, N. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15135303 · Cited by 2
“These studies reported reductions in proteinuria of approximately 20–35% and improved long-term renal outcomes [17–19].”
Sex-specific responses in the early stages of diet-induced cardiovascular-kidney-metabolic syndrome
Sharma, A., Deo, M., Tran, K. C. K., Tang, N. J., Bishop, T., Parker, A. N., Perera, N., Mesinovic, A., Gillis, R. D., Mamun, M. A. A., et al. (2026) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00724.2025 · Cited by 2
Yoo, D., Nguyen, V. K., Maggiore, U., & Jolliet, O. (2026) · PLOS Digital Health · doi:10.1371/journal.pdig.0001486 · Cited by 1
Bjornstad, P., Choi, Y. J., Narongkiatikhun, P., Karihaloo, A., Prasad, P. V., Li, L.-P., Tommerdahl, K. L., SETHI, M., Ramesh, S., Birznieks, C. L., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.aee1005 · Cited by 1
Pecoits-Filho, R., Banerjee, D., Jardine, M., Neuen, B. L., Soler, M. J., Ahmed, S. B., Anderson, L. J., Bavanandan, S., Bansal, S., Burton, J. O., et al. (2026) · Kidney International · doi:10.1016/j.kint.2026.06.044 · Cited by 2
Shen, N., Jin, S., Yue, Z., Song, Z., & Wu, M. (2026) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-026-02201-4 · Cited by 1
Henkel, L., Ingmanns, L., Westphal, F., Menke, A. F., Pavenstädt, H., Jehn, U., Boeckel, G. R., & Reuter, S. (2026) · Frontiers in Transplantation · doi:10.3389/frtra.2026.1927374 · Cited by 1
“The present findings may therefore primarily reflect early metabolic and hemodynamic changes, whereas potential longer-term effects on albuminuria and graft function would require larger prospective transplant cohorts with extended follow-up (2, 3).”
Light-activated CRISPR/dCas9 nanomedicine for programmable control of renal fibrosis
Taha, B. A., Addie, A. J., Haider, A. J., Ibnaouf, K., Apsari, R., & Arsad, N. (2026) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2026.113563 · Cited by 1
Öztürk, H. A., Gülümsek, E., Öztürk, D. D., Arıcı, F. N., Avcı, B. Ş., Işık, B., Erişen, M. C., Kaya, B. B., Alişan, İ., Dincer, C., et al. (2025) · Cukurova Anestezi ve Cerrahi Bilimler Dergisi · doi:10.36516/jocass.1654263 · Cited by 1
Dynamic lock-in compensation for mechanically dithered ring laser gyros
樊振方, 罗晖, 卢广峰, & 胡绍民 (2012) · Chinese Optics Letters · Cited by 1
Bakis, H., Pfirmann, P., Combe, C., & Rigothier, C. (2022) · Néphrologie & Thérapeutique · doi:10.1016/s1769-7255(22)00649-6 · Cited by 4
Blutdruckzielwerte bei eingeschränkter Nierenfunktion
van der Giet, M. (2023) · Die Innere Medizin · doi:10.1007/s00108-023-01483-4 · Cited by 1
HFpEF in Japan: When an Epidemiological Transition Becomes an Epidemiological Opportunity
Mitter, S. S., & Shah, S. J. (2023) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2023.02.005 · Cited by 1
Sourij, H., Edlinger, R., Prischl, F. C., Kaser, S., Horn, S., Antlanger, M., Paulweber, B., Aberer, F., Brix, J. M., Cejka, D., et al. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-022-02147-3 · Cited by 1
Treatment of Nondiabetic Kidney Diseases with Sodium-Glucose Cotransporter-2 Inhibitors
Brosius, F. C. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000194 · Cited by 2
Metadata
- Authors
- The EMPA-KIDNEY Collaborative Group
- Corresponding author
- The EMPA-KIDNEY Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-01-12
- Volume
- 388
- Issue
- 2
- Pages
- 117-127
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7614055
- OpenAlex
- W4308183941
- Cited by
- 2,754
- References
- 26
- Citations by year
- 2026: 727 · 2025: 759 · 2024: 734 · 2023: 520
- FWCI
- 321.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nd)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Docusalut (Conselleria de Salut i Consum del Govern de les Illes Balears) (submittedVersion, cc-by-nd)
- Hispana (submittedVersion, cc-by-nd)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Bristol Research (University of Bristol) (submittedVersion)
- Explore Bristol Research (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- Boehringer Ingelheim
- Eli Lilly and Company
- NIHR Biomedical Centre, Oxford
- Health Data Research
- Medical Research Council (MC_UU_00017/3 & MR/R007764/1)
- Kidney Research UK (MR/R007764/1)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- empagliflozin, chronic kidney disease, kidney disease progression, cardiovascular mortality, heart failure hospitalization, SGLT2 inhibitors, EMPA-KIDNEY trial, estimated glomerular filtration rate, diabetes mellitus
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Cardiovascular Diseases, Creatinine, Diabetes Mellitus, Type 2, Glomerular Filtration Rate, Glucosides, Humans, Kidney, Disease Progression, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.